Free Cash Flow

A NASDAQ-listed firm merges with a blockchain powerhouse, signaling a major shift for real-world asset tokenization and the future of finance.

A new oral drug, IMSB301, offers hope for Aicardi Goutières Syndrome, a devastating rare disease with no cure, in a pivotal new clinical trial.

The iconic brand is pivoting from its print legacy to a diversified lifestyle empire, and it has a new plan to convince investors it's the right move.

Align Partners launches a major governance overhaul campaign at Dentium, aiming to fix the 'Korea discount' and unlock value at the undervalued market leader.

The company reports a banner year with doubled free cash flow and EPS, launching a new $200M share buyback and signaling strong future growth.

The satellite firm unveils a complex debt shuffle and $1B capital raise, fueling its network vision while sending its stock tumbling on dilution fears.

The waste giant affirmed its quarterly dividend, backed by robust earnings and a positive outlook, highlighting sector stability and long-term value for investors.

Vynleads launches its Done With Diabetes app, using AI for daily support. But can it stand out in a crowded market and reverse its financial fortunes?

Moody's affirms the Estonian energy giant's Baa3 rating, but a negative outlook signals deep-seated risks from its oil shale legacy and market volatility.

A new Swiss FinTech, Lubit, launches a prediction market for energy, aiming to replace big-money trading with skill-based crowd intelligence.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

Amid a record backlog and major program milestones, CEO Kathy Warden is set to detail the defense giant's strategy at Citi's upcoming tech and mobility event.

Following key FDA progress for its oral osteoporosis drug, Entera Bio's CEO and board members are buying up company stock, signaling deep confidence.

Financially robust and debt-free, Rail Vision is rapidly expanding its AI safety systems globally while a new quantum computing arm aims to redefine the future of rail.

With a new OTCQB listing, Pecoy Copper aims to unlock U.S. capital for its massive Peruvian project amid a looming global copper shortage.

With major conferences ahead, clinical-stage MBX Biosciences aims to impress investors with its promising peptide therapies for endocrine and metabolic disorders.

Amid a surging aerospace market, StandardAero's upcoming earnings report is highly anticipated after a year of record growth and strategic expansion.

The defense contractor signals a strategic shift after lost contracts and procurement delays slash its 2027 revenue outlook, even as profits beat expectations.

Terex declared a steady dividend, but the real story is its surging stock and a bold forecast, revealing deep confidence in its strategic direction.

With key leadership promotions, AscellaHealth aims to streamline the complex path from drug discovery to patient delivery for life sciences companies worldwide.